These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 32228250)

  • 1. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of neuromyelitis optica.
    Duchow A; Chien C; Paul F; Bellmann-Strobl J
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
    Redenbaugh V; Flanagan EP
    Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
    Stathopoulos P; Dalakas MC
    Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
    Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
    Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
    Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
    Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on biologic treatments for neuromyelitis optica spectrum disorder.
    Kim W; Kim HJ
    Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Tisavipat N; Juan HY; Chen JJ
    Saudi J Ophthalmol; 2024; 38(1):2-12. PubMed ID: 38628414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
    Mader S; Kümpfel T; Meinl E
    Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.